A Phase 1/2 Study of Anti-CD19 CAR-T Therapy in Rheumatoid Arthritis

Active, Not Recruiting Phase 1,Phase 2 NCT06475495

Study Description

Comparing Anti-CD19 CAR-T Cell Therapy and Rituximab for Treating Rheumatoid Arthritis

Study Details

Registry ID:
NCT06475495
Conditions:
Rheumatoid Arthritis
Phase:
Phase 1,Phase 2
Target Enrollment:
13 participants
Start Date:
Age Range:
18–80 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →